Sign In
Last checked at 
6 Apr 2021 13:34
Director Dealing
York, U.K. 6th April 2021: Abingdon Health (AIM:ABDX) ("Abingdon" or "the Company"), a leading international developer and manufacturer of high quality and effective rapid tests, announces that Melanie Ross, Chief Financial Officer, has today purchased 5,338 ordinary shares of 0.025p each in the Company ("Ordinary Shares") at a price of 93.45 pence per Ordinary Share. Prior to this, Melanie did not hold an interest in any Ordinary Shares, and therefore has a resultant interest in 0.01% of the Company's issued share capital.
- Ends-
Enquiries:
Abingdon Health plc | ||||
Chris Yates | Chief Executive Officer | Via Consilium | ||
Melanie Ross | Chief Financial Officer | |||
Chris Hand | Non-Executive Chairman | |||
N+1 Singer | Sole Broker and Nominated Adviser | |||
Shaun Dobson, Peter Steel, | Tel: +44 (0) 20 7496 3000 | |||
Alex Bond (Corporate Finance) | ||||
Tom Salvesen (Corporate Broking) | ||||
Consilium | Financial PR | Tel: +44 (0) 203 709 5700 | ||
Matthew Neal | abingdonhealth@consilium-comms.com | |||
Mary-Jane Elliott | ||||
Lindsey Neville | ||||
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York, England.
https://www.abingdonhealth.com/
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name | Melanie Ross
| |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Financial Officer | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Abingdon Health plc | |||
b)
| LEI
| 213800XFI4WV3FBILO20
| |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of 0.025 pence each
| |||
Identification code | GB00BLF79J41 | ||||
b)
| Nature of the transaction
| Purchase of Ordinary Shares
| |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
93.45 pence | 5,338 | ||||
d)
| Aggregated information | N/A single transaction | |||
- Aggregated volume | |||||
- Price | |||||
e)
| Date of the transaction
| 6 April 2021 | |||
f)
| Place of the transaction
| London Stock Exchange
| |||
Follow the stocks
